4D Molecular Therapeutics (FDMT)
NASDAQ:FDMT
Want to see FDMT full AI Analyst Report?
Top Page
4D Molecular Therapeutics
(NASDAQ:FDMT)
Select Model
Select Model
Rating:50Neutral
Price Target:
$10.00
▼(-4.67% Downside)
Action:Reiterated
Date:05/09/26
Overall score reflects weak financial performance driven by large losses and sustained cash burn (primary drag), partially offset by a low-debt balance sheet and moderately positive technical setup with the stock trading above key moving averages. Valuation remains hard to assess due to negative earnings and no dividend yield data.
Positive Factors
Engineered AAV vector platform
A proprietary, tissue-targeted AAV vector platform is a durable competitive asset. It underpins multiple pipeline programs, can increase efficacy and tolerability versus non-targeted approaches, and strengthens partner appeal and licensing opportunities across ophthalmology and other indications.
Negative Factors
Sustained high cash burn
Large negative operating and free cash flows indicate ongoing funding needs. Persistent cash burn forces reliance on equity raises, partnerships, or milestone receipts, diluting shareholders or restricting R&D pacing and increasing execution risk over the next several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Engineered AAV vector platform
A proprietary, tissue-targeted AAV vector platform is a durable competitive asset. It underpins multiple pipeline programs, can increase efficacy and tolerability versus non-targeted approaches, and strengthens partner appeal and licensing opportunities across ophthalmology and other indications.
Read all positive factors
4D Molecular Therapeutics (FDMT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$478.31M
Dividend YieldN/A
Average Volume (3M)736.92K
Price to Earnings (P/E)―
Beta (1Y)0.84
Revenue Growth383560.87%
EPS Growth20.87%
CountryUS
Employees227
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.66
Shares Outstanding52,276,253
10 Day Avg. Volume751,996
30 Day Avg. Volume736,921
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)0.86
Price to Sales (P/S)5.10
P/FCF Ratio-3.98
Enterprise Value/Market Cap0.81
Enterprise Value/Revenue4.37
Enterprise Value/Gross Profit-35.09
Enterprise Value/Ebitda-2.15
Forecast
1Y Price Target
$29.00Price Target Upside176.45% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-3.91
Revenue Forecast (FY)$8.76M
4D Molecular Therapeutics Business Overview & Revenue Model
Company Description
4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalm...
How the Company Makes Money
FDMT generates revenue primarily through collaboration and licensing arrangements rather than product sales (its programs are clinical-stage and it has not consistently generated recurring commercial product revenue). Under these agreements, FDMT ...
4D Molecular Therapeutics Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
68
Positive
Cash Flow
34
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 88.24M | 85.21M | 37.00K | 20.72M | 3.13M | 18.04M |
| Gross Profit | -10.98M | 77.58M | 37.00K | -76.37M | -77.12M | -43.32M |
| EBITDA | -179.25M | -151.92M | -181.14M | -108.66M | -107.63M | -69.81M |
| Net Income | -160.90M | -140.11M | -160.87M | -100.84M | -107.49M | -71.32M |
Balance Sheet | ||||||
| Total Assets | 512.90M | 566.71M | 560.38M | 339.89M | 261.85M | 353.49M |
| Cash, Cash Equivalents and Short-Term Investments | 390.89M | 402.65M | 424.88M | 288.23M | 213.55M | 247.78M |
| Total Debt | 20.54M | 21.41M | 24.61M | 14.67M | 16.12M | 16.45M |
| Total Liabilities | 61.07M | 61.05M | 49.78M | 32.06M | 30.51M | 34.38M |
| Stockholders Equity | 451.84M | 505.66M | 510.61M | 307.83M | 231.34M | 319.11M |
Cash Flow | ||||||
| Free Cash Flow | -130.06M | -109.08M | -138.37M | -78.56M | -98.22M | -78.24M |
| Operating Cash Flow | -129.45M | -109.08M | -134.59M | -75.79M | -86.69M | -69.13M |
| Investing Cash Flow | -56.03M | -92.97M | -302.44M | 115.72M | -17.05M | -172.68M |
| Financing Cash Flow | 124.44M | 112.96M | 337.25M | 156.83M | 3.08M | 118.09M |
4D Molecular Therapeutics Technical Analysis
Negative
10.49
Price Trends
9.48
Negative
9.00
Negative
8.94
Negative
Market Momentum
-0.02
Positive
37.61
Neutral
14.85
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FDMT, the sentiment is Negative. The current price of 10.49 is above the 20-day moving average (MA) of 9.64, above the 50-day MA of 9.48, and above the 200-day MA of 8.94, indicating a bearish trend. The MACD of -0.02 indicates Positive momentum. The RSI at 37.61 is Neutral, neither overbought nor oversold. The STOCH value of 14.85 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FDMT.
4D Molecular Therapeutics Risk Analysis
4D Molecular Therapeutics disclosed 87 risk factors in its most recent earnings report. 4D Molecular Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
4D Molecular Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | $897.51M | -9.27 | -33.07% | ― | ― | -20.34% | |
52 Neutral | $455.32M | -12.91 | -4.21% | ― | 121.11% | 80.74% | |
52 Neutral | $800.21M | -3.35 | -78.12% | ― | ― | 7.21% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $478.31M | -2.30 | -36.83% | ― | 383560.87% | 20.87% | |
49 Neutral | $146.82M | -1.67 | -117.86% | ― | -20.31% | -23.75% | |
46 Neutral | $333.84M | -6.33 | -0.11% | ― | ― | 40.79% |
* Healthcare Sector Average
FDMT
4D Molecular Therapeutics
8.37
4.57
120.13%
ASMB
Assembly Biosciences
27.42
13.62
98.70%
KRRO
Korro Bio
9.97
-5.74
-36.54%
DSGN
Design Therapeutics
10.70
7.17
203.12%
IMRX
Immuneering
4.87
3.35
220.39%
AURA
Aura Biosciences Inc
7.47
1.55
26.18%
4D Molecular Therapeutics Corporate Events
Business Operations and StrategyExecutive/Board Changes
4D Molecular Therapeutics Consolidates Financial Leadership Under New Role
Positive
Mar 31, 2026
On March 25, 2026, 4D Molecular Therapeutics appointed Chief Financial Officer Kristian Humer as its Principal Accounting Officer, consolidating key financial leadership roles under a single executive. He replaces Ashoo Gupta in this capacity, who...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.